1
Return

Genomic Determinants and an Exploratory Prognostic Model for Immunotherapy Outcomes in Recurrent or Metastatic Cervical Cancer

delete2026-06-22
delete0
delete
OA
AI
L
Lingling Gu
B
Biqing Zhu
C
Cuicui Liu
X
Xiaoying Wu
Y
Yaru Zhang
J
Jiani Yin
F
Fufeng Wang
T
Tingting Hu *
Y
Yaqin Wu *
DOI：10.1093/oncolo/oyag236delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Immune checkpoint inhibitors (ICIs) improve outcomes in recurrent or metastatic cervical cancer, but responses are heterogeneous and biomarkers beyond programmed death-ligand 1 (PD-L1) are limited.

Journal

T
The Oncologist
IF:
0
Papers:
188
Citations:
0

Organization

J
Jiangsu Cancer Hospital
Scholars:
69
Papers: 28
Citations: 2.3K
N
nanjing geneseeq technology inc
Scholars:
60
Papers: 14
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers